RNA Platforms: What Transfers And What Breaks

By Jyotsna Jajula, research assistant, Wayne State University

RNA platforms promise reuse, but biology does not reliably cooperate. This tension is becoming more important as RNA therapeutics expand beyond vaccines into oncology, rare diseases, gene editing, protein replacement, immune modulation, and regenerative medicine. Developers increasingly rely on knowledge from earlier programs to guide future development, but not every lesson carries the same predictive value.¹

Manufacturing workflows, analytical methods, formulation principles, quality systems, and regulatory experience can provide a reusable foundation across RNA programs. When applied appropriately, this knowledge reduces duplication, shortens development timelines, improves process control, and supports more efficient decision-making.^2,3

The central question is not whether RNA platforms are valuable. The more important question is where platform knowledge can be reused with verification, where it requires structured adaptation, and where it must be treated as a new hypothesis requiring direct evidence.²

Why Platform Thinking Matters

RNA programs share core technical foundations, including RNA design, synthesis, purification, analytical characterization, formulation development, quality control, and regulatory documentation. When developers build these elements systematically, they create a knowledge base that supports multiple programs rather than requiring each product to begin from the same starting point.^2,3

Yet a platform should not be viewed as a fixed solution that works across all RNA applications. It is better understood as a structured knowledge system. Some components are process controlled and highly transferable. Others are product dependent and require adaptation. The least predictable areas are biologically emergent, where performance depends on tissue architecture, disease state, immune tone, cell type, dose, and clinical setting.^2,4

The opportunity of platform thinking is speed, efficiency, and consistency. The responsibility is scientific discipline. Platform knowledge should accelerate development where evidence is strong, but it should not replace evidence where the biological context has changed.^2,4

The RNA Transferability Framework

Not all platform knowledge behaves the same when transferred. Transferability in RNA development should be treated as a decision framework, not a yes or no label. Different types of knowledge require different levels of evidence before they can be applied to a new program.^2,4

High transferability knowledge is generally process controlled. Manufacturing workflows, analytical methods, quality systems, and documentation practices can be reused with verification because they are shaped mainly by process science, analytical principles, and quality control.^2,5

Moderate transferability knowledge is usually product dependent. Formulation design, stability strategy, scale-up, and process optimization may benefit from prior experience, but they require structured adaptation. Differences in RNA length, sequence, chemical modification, concentration, formulation composition, and intended clinical use can change product behavior.^3,4

Low transferability knowledge is biologically emergent. Biodistribution, tissue targeting, efficacy, immune activation, therapeutic index, repeat dose tolerability, and long-term safety should be treated as new evidence generation. These outcomes depend on tissue biology, disease state, dosing paradigm, patient population, and therapeutic objective.^3,4

This framework helps developers avoid two common errors. One error is repeating work that prior experience could inform. The opposite error is assuming that platform success in one setting will automatically predict performance in another. The stronger approach is to match the type of knowledge being transferred with the level of evidence required to support that transfer.⁴

Teams can operate this framework by documenting transfer assumptions at program start and linking each assumption to required verification, adaptation studies, or new evidence generation.¹

Where Knowledge Transfers Well

RNA platform knowledge transfers most reliably when process science, analytical principles, and quality control govern the outcome. These areas are not independent of product attributes, but they are less dependent on complex biology than clinical performance or tissue targeting.^2,4

Manufacturing workflows are the clearest example. Prior experience with RNA synthesis, in vitro transcription, purification, impurity control, and process monitoring can help teams anticipate technical challenges and support future candidates more efficiently.⁵

Analytical characterization also has strong transferability. Methods used to evaluate RNA identity, purity, integrity, potency, residual impurities, encapsulation, and product consistency can inform subsequent programs. Product-specific validation or qualification may still be required, but prior assay development can improve method selection.^2,5

Quality systems provide a broader platform foundation. Documentation practices, release testing frameworks, deviation management, process controls, and comparability strategies create consistency across programs. Regulatory experience can also inform strategy around product characterization, manufacturing controls, stability data, safety evaluation, and clinical development planning.^2,4

However, regulatory familiarity should not be confused with product approval logic. Each product still requires its own evidence package. Platform knowledge can define the starting conditions of development, but each RNA program requires confirmation that the process, methods, and controls fit its specific product profile.⁴

Where Knowledge Requires Adaptation

Moderate transferability areas are shaped by both platform experience and product-specific variables. Formulation development, stability strategy, scale-up, and process optimization fall into this category because they depend on physicochemical properties as well as manufacturing conditions.^6,7

Prior experience with lipid nanoparticles or other delivery systems can guide excipient selection, particle characterization, encapsulation strategy, and stability testing. However, formulation behavior can shift when there are changes in RNA length, sequence, structure, charge, chemical modification, concentration, or intended dose. These variables directly affect encapsulation efficiency, particle size distribution, release behavior, and downstream biological performance.^6,7

Stability strategies also require adaptation. RNA products are sensitive to degradation, and stability can be affected by formulation composition, buffer conditions, storage temperature, container closure system, freeze thaw exposure, and handling procedures. Previous stability data may identify likely risks, but it cannot fully predict degradation behavior for a new product.^8,9

Scale-up has similar limits. A process that performs well at small scale may behave differently in larger batches because mixing conditions, process timing, filtration, equipment geometry, shear stress, and fill/finish operations can influence product quality.⁵

In these areas, prior knowledge should guide the experimental plan, not replace it. Developers should define which assumptions are being reused, which variables have changed, and which studies are needed to confirm that the platform approach remains valid.⁵

Where Knowledge Fails To Transfer Reliably

RNA platform knowledge transfers least reliably when biological systems govern outcomes. Biodistribution, tissue targeting, cellular uptake, endosomal escape, immune activation, efficacy, therapeutic index, repeat dose tolerability, and long-term safety are shaped by the environment in which the RNA therapeutic must function.^6,10

The mechanistic reasons matter. Tissue access can differ dramatically across organs. Fenestrated liver endothelium may permit nanoparticle access that is not replicated in tissues with tighter endothelial barriers, such as muscle or brain. Receptor density, cell surface composition, extracellular matrix structure, local blood flow, and disease-associated remodeling can all alter delivery and exposure.¹⁰

Cellular uptake is also not equivalent across tissues. A delivery system that enters one cell population efficiently may perform poorly in another because uptake pathways, intracellular trafficking, and endosomal escape efficiency vary across cell types. Endosomal escape is especially important because internalization alone does not ensure productive delivery. The RNA must reach the cytosol in sufficient quantity to generate the intended biological effect.¹²

Immune biology adds another layer of uncertainty. RNA therapeutics can interact with innate immune sensing pathways, including endosomal and cytosolic RNA sensors. A response that is beneficial in a vaccine context may become limiting in a chronic therapeutic setting.^13,14

For these reasons, biological and clinical knowledge should be treated as low transferability knowledge. Prior platform experience can inform hypotheses and study design, but it cannot replace direct evidence in the relevant tissue, disease, dosing paradigm, and patient population.^10,13

Two Transitions That Illustrate The Problem

The transition from mRNA vaccine experience to chronic protein replacement therapies shows why transferability must be evaluated carefully.^15,16

Manufacturing workflows, analytical methods, quality systems, and some formulation principles can provide a useful starting point. In contrast, assumptions about immune activation, expression duration, dosing frequency, and tolerability thresholds may not hold in a chronic therapeutic setting. Developers must demonstrate protein expression control, repeat dose feasibility, durability, inflammatory burden, and chronic safety margin.^2,15,16

A second example is the movement from liver-directed RNA programs to extrahepatic delivery.¹⁰ Systemic administration experience, formulation knowledge, manufacturing controls, and early safety assessment strategies can transfer at the operational level. In contrast, assumptions about tissue exposure, receptor availability, cellular uptake, endosomal escape, and therapeutic index must be reassessed. Developers must newly demonstrate delivery to the intended tissue, productive cellular entry, target engagement, efficacy, and context-specific safety.¹⁰

These transitions show why platform knowledge is valuable but conditional. A previous program can define the starting point, but the new biological context determines what must be proved again.^10,15

Where Platform Assumptions Create Risk

Platform assumptions become risky when they outpace the evidence required to support them. This risk is most likely when a program enters a new biological context while relying heavily on knowledge generated in a different setting.⁴

The problem is not platform thinking itself. The risk is untested transfer. Manufacturing experience may transfer. Analytical methods may provide a starting point. Regulatory learning may inform strategy. But biological performance still needs to be demonstrated directly when the therapeutic context changes.⁴

When organizations fail to make this distinction, they may underestimate development risk, design insufficient studies, or delay critical experiments until later stages. These decisions can affect study design, cost, regulatory strategy, and clinical probability of success.⁴

Building Smarter RNA Platforms

The future of RNA platform development should focus on precision in transferability rather than breadth of claims. A strong RNA platform should clearly separate reusable infrastructure from program-specific evidence.⁴

Reusable infrastructure may include manufacturing systems, analytical frameworks, documentation templates, quality procedures, formulation experience, and regulatory knowledge. Program-specific evidence should include tissue delivery, biological activity, dose response, safety, durability, and clinical relevance.⁴

Smarter RNA platforms function best as learning systems. Each program should use prior platform knowledge and contribute new information back to the platform. Over time, this creates a more refined understanding of which assumptions are reliable, conditional, or context dependent.⁴

This approach enables speed where evidence is strong and enforces deeper validation where biological uncertainty remains high.

Conclusion

RNA platform development will continue to shape the future of RNA therapeutics. Reusable manufacturing knowledge, analytical methods, quality systems, formulation experience, and regulatory learning can provide major advantages in speed, efficiency, and scalability.

However, platform knowledge has boundaries. Operational knowledge often transfers well because it is largely process controlled. Product development knowledge may transfer with adaptation because it is influenced by physicochemical and formulation variables. Biological and clinical knowledge require the greatest caution because they are shaped by tissue context, disease biology, therapeutic objective, dosing paradigm, immune response, and patient variability.

The most successful RNA developers may not be those that assume platform knowledge transfers automatically. They may be those that know precisely when it transfers, when it requires modification, and when new evidence must be generated.

The competitive advantage in RNA therapeutics is shifting. It is no longer defined by platform breadth alone but by precision in applying platform knowledge: knowing what transfers, what must be adapted, and what must be rebuilt.

References:

1. Makkar SK. Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Frontiers in Genetics. 2025;16:1675209. doi:10.3389/fgene.2025.1675209.
2. Skerritt JH. Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines. 2025;13(5):473. doi:10.3390/vaccines13050473.
3. Camperi J, Chatla K, Freund E, Galan C, Lippold S, Guilbaud A. Current analytical strategies for mRNA-based therapeutics. Molecules. 2025;30(7):1629. doi:10.3390/molecules30071629.
4. Skerritt JH. The platform technology approach to mRNA product regulation. Vaccines. 2024;12(5):528. doi:10.3390/vaccines12050528.
5. Nowak CJA, Liu S, Gerstweiler L. Process and analytical strategies for the safe production of mRNA vaccines and therapeutics. Molecular Biology Reports. 2026;53(1):306. doi:10.1007/s11033-026-11455-0.
6. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6:1078-1094. doi:10.1038/s41578-021-00358-0.
7. Li X, Li S, et al. Design strategies for novel lipid nanoparticle for mRNA vaccine and therapeutics: current understandings and future perspectives. MedComm. 2025. doi:10.1002/mco2.70414.
8. Nomani A, Saraswat A, Brown H, Kuo JCT, Duong HTT, Wu J, et al. Identifying key factors affecting mRNA-lipid nanoparticles drug product formulation stability. Nanomaterials. 2026;16(4):268. doi:10.3390/nano16040268.
9. Sato M, Samaridou E, Beck-Broichsitter M, Maeki M, Kita S, Tokeshi M, et al. Examining the impact of storage conditions on the stability of a liquid formulation of mRNA-loaded lipid nanoparticles. Pharmaceutics. 2025;17(9):1194. doi:10.3390/pharmaceutics17091194.
10. Dalabehera M, Ghosh A, Mohanty S, Chellappan DK, Chaudhari S, Ale Y, et al. mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics. Materials Today Bio. 2025;35:102584. doi:10.1016/j.mtbio.2025.102584.
11. Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: A bottleneck for LNP-mediated therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(11):e2307800120. doi:10.1073/pnas.2307800120.
12. Luan X, Wang L, Song G, Zhou W. Innate immune responses to RNA: sensing and signaling. Frontiers in Immunology. 2024;15:1287940. doi:10.3389/fimmu.2024.1287940.
13. Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Experimental & Molecular Medicine. 2023;55:2085-2096. doi:10.1038/s12276-023-01086-x.
14. Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nature Biotechnology. 2022;40:1586-1600. doi:10.1038/s41587-022-01491-z.
15. World Health Organization. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations. Geneva: World Health Organization; 2021.

About The Author:

Jyotsna Jajula is a research assistant at Wayne State University. Her work broadly explores RNA delivery mechanisms in oncology cell models, with a focus on internalization and cytoplasmic fate of therapeutic peptides. Jajula holds a master’s degree in pharmaceutical sciences and has prior research experience in lipid nanoparticles, RNA stability, and biodistribution strategies across oncology, immunology, and gene-therapy applications.